HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs - Seite 2

HOOKIPA will reduce its workforce by approximately 30 percent and rebalance its cost structure in alignment with the new prioritization of the Company’s programs. HOOKIPA maintains a strong cash position of $117.5 million¹ as of December 31, 2023, and believes that the planned reductions will help to conserve resources and better align its organization in direct support of late-stage clinical development efforts.

Pipeline Update and Upcoming Catalysts-

The strategic priorities for HOOKIPA are to advance its clinical programs including HB-200 and its two Gilead-partnered infectious disease programs. The Company is planning to submit an IND for HB-700 in the first quarter of 2024 and will begin searching for a collaboration partner. At this time, the company will not pursue further preclinical programs into development and pause further development of its HB-300 to conserve capital and ensure pipeline success and operational efficiency.

Program	Indication	Upcoming Catalysts
Oncology Programs
HB-200	HPV16+ HNSCC	Additional first-line data for HB-200 in combination with pembrolizumab (1H 2024) Initiation of randomized trial (mid-2024)
HB-700	KRAS	IND submission (1Q 2024) Publication of preclinical research (1H 2024) Search for new collaboration partner
Infectious Disease Programs: Gilead-Partnered
HB-400	HBV	Gilead-led: Phase 1b actively enrolling Next milestone: Phase 2 initiation (Timing TBD)
HB-500	HIV	Initiation of Phase 1 trial First patient dosed, milestone payment (1H 2024)
Paused Programs
HB-300	Prostate Cancer	Paused and utilize capital to support HB-200 development
Preclinical	Multiple targets

¹ Cash position as of December 31, 2023, is unaudited